Combining 18F-FDG PET/CT–Based Metabolically Active Tumor Volume and Circulating Cell-Free DNA Significantly Improves Outcome Prediction in Chemorefractory Metastatic Colorectal Cancer

Baseline whole-body metabolically active tumor volume (WB-MATV) measured by 18F-FDG PET/CT and circulating cell-free DNA (cfDNA) have been separately validated as predictors of overall and progression-free survival (OS/PFS) in chemorefractory metastatic colorectal cancer (mCRC) patients. This study assessed the correlation between WB-MATV and cfDNA, evaluating the added prognostic value of these in combination, along with clinical parameters. Methods: Of 141 mCRC patients included in a prospective multicenter trial, 132 were evaluable for OS/PFS. cfDNA was extracted from 3 mL of plasma and quantified using a fluorometer. All target lesions were delineated on 18F-FDG PET/CT, and their metabolic volumes were summed to obtain the WB-MATV. Results: Baseline WB-MATV and cfDNA were strongly correlated (r = 0.70; P < 0.001) but showed discordance in 23 of 132 (17%) patients. A multivariate analysis identified 3 independent negative predictors of PFS (high cfDNA, short time since diagnosis, and body mass index < 30) and 5 of OS (high cfDNA, high WB-MATV, body mass index < 30, poor performance status, and short time since diagnosis). Combining WB-MATV and cfDNA increased the overall prognostic value and allowed identification of a subgroup of patients with low cfDNA and high WB-MATV who were associated with intermediate survival (median OS of 8.1 for low-cfDNA/high-MATV patients vs. 12.7 mo for low-cfDNA/low-MATV patients; hazard ratio, 2.04; P = 0.02). Conclusion: This study confirms the added prognostic value of combined circulating cfDNA and PET-based WB-MATV in chemorefractory mCRC patients. The combination of these two biomarkers should provide a firm basis for risk stratification, both in clinical practice and in research trials.

[1]  P. Flamen,et al.  Validation of Metabolically Active Tumor Volume and Total Lesion Glycolysis as 18F-FDG PET/CT–derived Prognostic Biomarkers in Chemorefractory Metastatic Colorectal Cancer , 2019, The Journal of Nuclear Medicine.

[2]  P. Flamen,et al.  Metabolic Active Tumor Volume and Total Lesion Glycolysis by 18 F-FDG PET/CT Validated as Prognostic Imaging Biomarkers in Chemorefractory Metastatic Colorectal Cancer , 2018 .

[3]  I. Brandslund,et al.  Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis. , 2017, The oncologist.

[4]  C. Demuth,et al.  Correlation between circulating mutant DNA and metabolic tumour burden in advanced non-small cell lung cancer patients , 2017, British Journal of Cancer.

[5]  R. Boellaard,et al.  EANM/EARL harmonization strategies in PET quantification: from daily practice to multicentre oncological studies , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[6]  S. Morbelli,et al.  Circulating Tumor DNA Reflects Tumor Metabolism Rather Than Tumor Burden in Chemotherapy-Naive Patients with Advanced Non–Small Cell Lung Cancer: 18F-FDG PET/CT Study , 2017, The Journal of Nuclear Medicine.

[7]  Daniel J Sargent,et al.  Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  G. Beretta,et al.  Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Seung-Yong Jeong,et al.  Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  A. Bronkhorst,et al.  Cell-free DNA: Preanalytical variables. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[11]  J. Zavadil,et al.  Circulating free DNA concentration is an independent prognostic biomarker in lung cancer , 2015, European Respiratory Journal.

[12]  D. Sargent,et al.  Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial. , 2015, The Lancet. Oncology.

[13]  I. Brandslund,et al.  Controls to validate plasma samples for cell free DNA quantification. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[14]  Paul Kinahan,et al.  Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials , 2015, The Journal of Nuclear Medicine.

[15]  P. Flamen,et al.  Regorafenib assessment in refractory advanced colorectal cancer: RegARd-C study protocol , 2015, BMJ Open.

[16]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[17]  R. Pandey,et al.  High Levels of Cell-Free Circulating Nucleic Acids in Pancreatic Cancer are Associated With Vascular Encasement, Metastasis and Poor Survival , 2015, Cancer investigation.

[18]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  P. Holdgaard,et al.  The correlation between cell-free DNA and tumour burden was estimated by PET/CT in patients with advanced NSCLC , 2013, British Journal of Cancer.

[20]  F. Mouliere,et al.  Circulating cell free DNA: Preanalytical considerations. , 2013, Clinica chimica acta; international journal of clinical chemistry.

[21]  Carlos Caldas,et al.  Analysis of circulating tumor DNA to monitor metastatic breast cancer. , 2013, The New England journal of medicine.

[22]  U. Banerji,et al.  Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers , 2012, PloS one.

[23]  R. Rosell,et al.  Circulating DNA is a Useful Prognostic Factor in Patients with Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[24]  K. Jung,et al.  Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[25]  M. Ychou,et al.  Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts , 2010, Nucleic acids research.

[26]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[27]  T. Dorff,et al.  Multimarker circulating DNA assay for assessing blood of prostate cancer patients. , 2009, Clinical chemistry.

[28]  K. Kinzler,et al.  Serial assessment of human tumor burdens in mice by the analysis of circulating DNA. , 2007, Cancer research.

[29]  W. Oyen,et al.  FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  Sumithra J. Mandrekar,et al.  Finding Optimal Cutpoints for Continuous Covariates with Binary and Time-to-Event Outcomes , 2006 .

[31]  W. Scheithauer,et al.  Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  L. Påhlman,et al.  Appraisal of a model for prediction of prognosis in advanced colorectal cancer. , 1994, European journal of cancer.